SpringWorks Therapeutics

BALTIMORE, MD · Founded 2017 · Biotech · Acquired

Small molecule and biologic cancer therapeutics

Claim this profile

Follows are private to you and power your alerts

Updated · springworkstx.com

Sector
Biotech
Headquarters
BALTIMORE, MD
Founded
2017
Latest Form D
$12.8M, Sep 2017
Total capital
$12.8M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$12.8M
1 Form D · last Sep 2017
110 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
18
22 pending · first 2024
Rank in peer group#40 of 1449

Capital timeline

2017FEDERAL ↑EQUITY ↓Cumulative $12.8M1st Form D$12.8M
2017FEDERAL ↑EQUITY ↓Cumulative $12.8M1st Form D$12.8M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$12.8M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#40 · top 3%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Carl GordonDirectorNamed in SEC Form D filings
  • Carl L GordonDirectorNamed in SEC Form D filings
  • Daniel S. LynchExecutive Officer, DirectorNamed in SEC Form D filings
  • Daniel S. LynchExecutive Officer, DirectorNamed in SEC Form D filings
  • Deval PatrickDirectorNamed in SEC Form D filings
  • Freda Lewis-HallDirectorNamed in SEC Form D filings
Show all 14 people
  • Freda Lewis-Hall, M.D.DirectorNamed in SEC Form D filings
  • Jeffrey SchwartzDirectorNamed in SEC Form D filings
  • Jeff SchwartzDirectorNamed in SEC Form D filings
  • Lara Sullivan, M.D.Executive Officer, DirectorNamed in SEC Form D filings
  • Michael GrecoExecutive OfficerNamed in SEC Form D filings
  • Peter KeenDirectorNamed in SEC Form D filings
  • Saqib IslamExecutive Officer, DirectorNamed in SEC Form D filings
  • Stephen SquintoDirectorNamed in SEC Form D filings

What it has protected

USPTO · 18 granted of 40
Show all 40 patent records
  • Hoth Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Cristcot LLCSimilar federal contract value in Biotech · null in contracts
  • Angiex, Inc.Similar federal contract value in Biotech · null in contracts
  • ALAMAB THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
  • Alkahest, Inc.Similar federal contract value in Biotech · null in contracts
  • Evercrisp Biosciences, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .